Cancer Therapy

Latest preclinical study suggests broader potential utility of MDM2 antisense

Published in Cancer Weekly, March 23rd, 2004

Hybridon, Inc., (HBY) announced the publication of a preclinical research report presenting evidence in cells and cell lysates that the MDM2 oncoprotein decreases the activity of the tumor suppressor protein p21 through direct physical interaction.

MDM2 is the target of Hybridon's second-generation antisense drug candidate GEM240.

The paper, titled "MDM2 is a Negative Regulator of p21waf1/cip1, Independent of p53" and published in the February 2004 Journal of Biological Chemistry, is co-authored by Ruiwen Zhang, Zhuo Zhang, Hui Wang, Mao Li, and Xinbin Chen from the University of Alabama at Birmingham (Alabama) (UAB), and Sudhir Agrawal,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-03-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry